Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;47(2):211-247.
doi: 10.1097/FTD.0000000000001243. Epub 2024 Sep 11.

Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review

Affiliations

Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review

Angela Wu et al. Ther Drug Monit. .

Abstract

Background: Pharmacogenetic testing in clinical settings has improved the safety and efficacy of drug treatment. There is a growing number of studies evaluating pharmacogenetic implementation and identifying barriers and facilitators. However, no review has focused on bridging the gap between identifying barriers and facilitators of testing and the clinical strategies adopted in response. This review was conducted to understand the implementation and evaluation strategies of pharmacogenetic testing programs.

Methods: A PRISMA-compliant scoping review was conducted. The included studies discussed pharmacogenetic testing programs implemented in a hospital setting. Quantitative, qualitative, and mixed design methods were included.

Results: A total of 232 of the 7043 articles that described clinical pharmacogenetic programs were included. The most common specialties that described pharmacogenetic implementation were psychiatry (26%) and oncology (16%), although many studies described institutional programs implemented across multiple specialties (19%). Different specialties reported different clinical outcomes, but all reported similar program performance indicators, such as test uptake and the number of times the test recommendations were followed. There were benefits and drawbacks to delivering test results through research personnel, pharmacists, and electronic alerts, but active engagement of physicians was necessary for the incorporation of pharmacogenetic results into clinical decision making.

Conclusions: Further research is required on the maintenance and sustainability of pharmacogenetic testing initiatives. These findings provide an overview of the implementation and evaluation strategies of different specialties that can be used to improve pharmacogenetic testing.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Similar articles

Cited by

References

    1. Haga SB, Burke W. Using pharmacogenetics to improve drug safety and efficacy. JAMA. 2004;291:2869–2871.
    1. Borden BA, Lee SM, Danahey K, et al. Point-of-care provider use of pharmacogenomic (PGX) results during prescribing impacts patient (PT) recall of medication recommendations. Clin Pharmacol Ther. 2017;101(suppl 1):S22.
    1. Somogy A. Evolution of pharmacogenomics. Proc West Pharmacol Soc. 2008;51:1–4.
    1. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6–13.
    1. U.S. Food and Drug Administration. Table of Pharmacogenetic Associations; 2022. Available at: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogen... . Accessed February 19, 2023.

Publication types

LinkOut - more resources